Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

2.50
Hdl Handle:
http://hdl.handle.net/2436/29484
Title:
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
Authors:
Wang, Weiguang; Marsh, S.; Cassidy, James; McLeod, Howard
Abstract:
Chemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered expression are the main genetic mechanisms of tumor chemoresistance. Previously, only a limited number of genes were analyzed in each individual study using traditional molecular methods such as Northern and Southern blotting. In this study, the global gene expression patterns of 1176 genes in a panel of five thymidylate synthase (TS) inhibitor [raltitrexed (TDX) and 5-fluorouracil (5-FU)] resistant and sensitive parent cell lines were investigated using cDNA array technology. Only 28 of 1176 genes were altered >1.5-fold among resistant cells, with 2 genes (TS and YES1) consistently higher in the panel. TS mRNA and protein were consistently overexpressed in all drug-resistant tumor cell lines compared with the sensitive parent cell lines. Southern blot and FISH analysis demonstrated that the TS gene was amplified in 5-FU- and TDX-resistant cell lines. YES1 mRNA and protein were overexpressed in four drug-resistant tumor cell lines but were not overexpressed in the lymphoblast cell line W1L2(TDX), although the YES1 gene was highly amplified in these cells. The fact that W1L2 has high level (>10-fold) resistance to TS inhibitor in the absence of high YES1 expression leads to a conclusion that YES1 has no direct role in this drug resistance process. By narrowing the search from 1176 to 2 genes, the analysis of in vitro TDX and 5-FU resistance becomes more straightforward for confirmatory studies. These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics.
Citation:
Cancer Research, 61 (14): 5505-10
Publisher:
American Association for Cancer Research
Journal:
Cancer Research
Issue Date:
2001
URI:
http://hdl.handle.net/2436/29484
PubMed ID:
11454699
Additional Links:
http://cancerres.aacrjournals.org/cgi/content/full/61/14/5505
Type:
Article
Language:
en
ISSN:
0008-5472
Appears in Collections:
Cancer Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorWang, Weiguang-
dc.contributor.authorMarsh, S.-
dc.contributor.authorCassidy, James-
dc.contributor.authorMcLeod, Howard-
dc.date.accessioned2008-06-04T13:09:52Z-
dc.date.available2008-06-04T13:09:52Z-
dc.date.issued2001-
dc.identifier.citationCancer Research, 61 (14): 5505-10en
dc.identifier.issn0008-5472-
dc.identifier.pmid11454699-
dc.identifier.urihttp://hdl.handle.net/2436/29484-
dc.description.abstractChemoresistance is a major obstacle for successful cancer treatment. Gene amplification and altered expression are the main genetic mechanisms of tumor chemoresistance. Previously, only a limited number of genes were analyzed in each individual study using traditional molecular methods such as Northern and Southern blotting. In this study, the global gene expression patterns of 1176 genes in a panel of five thymidylate synthase (TS) inhibitor [raltitrexed (TDX) and 5-fluorouracil (5-FU)] resistant and sensitive parent cell lines were investigated using cDNA array technology. Only 28 of 1176 genes were altered >1.5-fold among resistant cells, with 2 genes (TS and YES1) consistently higher in the panel. TS mRNA and protein were consistently overexpressed in all drug-resistant tumor cell lines compared with the sensitive parent cell lines. Southern blot and FISH analysis demonstrated that the TS gene was amplified in 5-FU- and TDX-resistant cell lines. YES1 mRNA and protein were overexpressed in four drug-resistant tumor cell lines but were not overexpressed in the lymphoblast cell line W1L2(TDX), although the YES1 gene was highly amplified in these cells. The fact that W1L2 has high level (>10-fold) resistance to TS inhibitor in the absence of high YES1 expression leads to a conclusion that YES1 has no direct role in this drug resistance process. By narrowing the search from 1176 to 2 genes, the analysis of in vitro TDX and 5-FU resistance becomes more straightforward for confirmatory studies. These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics.en
dc.language.isoenen
dc.publisherAmerican Association for Cancer Researchen
dc.relation.urlhttp://cancerres.aacrjournals.org/cgi/content/full/61/14/5505en
dc.subject.meshBlotting, Northernen
dc.subject.meshBlotting, Westernen
dc.subject.meshDrug Resistance, Neoplasmen
dc.subject.meshEnzyme Inhibitorsen
dc.subject.meshFluorouracilen
dc.subject.meshGene Expression Regulation, Neoplasticen
dc.subject.meshHumansen
dc.subject.meshIn Situ Hybridization, Fluorescenceen
dc.subject.meshOligonucleotide Array Sequence Analysisen
dc.subject.meshProto-Oncogene Proteinsen
dc.subject.meshProto-Oncogene Proteins c-yesen
dc.subject.meshQuinazolinesen
dc.subject.meshRNA, Messengeren
dc.subject.meshThiophenesen
dc.subject.meshThymidylate Synthaseen
dc.subject.meshTumor Cells, Cultureden
dc.subject.meshsrc-Family Kinasesen
dc.titlePharmacogenomic dissection of resistance to thymidylate synthase inhibitors.en
dc.typeArticleen
dc.identifier.journalCancer Researchen
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.